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Abstract
Introduction Women with inherited metabolic disorders, in-
cluding those with previously life-limiting conditions such as
MMA, are reaching child-bearing age more often due to
advances in early diagnosis and improved pediatric care.
Information surrounding maternal and fetal complications
associated with the underlying disorders remains largely
unexplored.
Methods Pregnancies affected by maternal MMA were
ascertained through study 04-HG-0127 “Clinical and Basic
Investigations of Methylmalonic Acidemia and Related Dis-
orders” (clinicaltrials.gov identifier: NCT00078078) and via
literature review. Prenatal and delivery records in study par-
ticipants were reviewed.
Results Seventeen pregnancies were identified in womenwith
isolated MMA, including three abortions, one termination,
and 13 completed pregnancies [three cases with cblA (four
pregnancies), four cases of mut- (one cobalamin responsive,
three non-responsive), five cases with unknown type of
MMA]. Seventeen percent (3/17) of the pregnancies resulted
in a first trimester abortion, while 38.5 % (5/13) of the com-
pleted pregnancies resulted in preterm deliveries. A cesarean
delivery rate of 53.8 % (7/13) was noted among the cohort.
Fetal distress or nonreassuring fetal status was the indication
for 57% (4/7) cesarean deliveries. One patient was reported to
have metabolic crisis as well as episodes of mild
hyperammonemia. Malformations or adverse outcomes in
the progeny were not observed.
Conclusion Although there have been a small number of
pregnancies identified in women with MMA, the cumulative
results suggest that the majority of pregnancies can be com-
plicated by cesarean delivery and increased risk of prematuri-
ty. A pregnancy registry could clarify perinatal complications
and define management approaches needed to ensure optimal
maternal and fetal outcomes in this growing patient
population.
Introduction
Methylmalonic acidemia (MMA) is a group of inherited met-
abolic disorders with a common defect in the conversion of
methylmalonyl-CoA to succinyl-CoA (Manoli and Venditti
2010). The disorder was first defined clinically in late 1960s in
infants presenting with overwhelming acidosis and renal tu-
bular dysfunction (Oberholzer et al 1967; Stokke et al 1967).
MMA is most commonly caused by mutations in the mito-
chondrial localized enzyme, methylmalonyl-CoA mutase
(MUT) or impaired transport and synthesis of the MUT co-
factor, 5′-deoxyadenosylcobalamin due to mutations in the
MMAA, MMAB or MMADHC genes (Chandler and Venditti
2005). Over the past four decades, treatment with amino acid/
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protein precursor restriction, along with supportive care and
supplementation with cobalamin in responsive patients, has
led to improved survival (de Baulny et al 2005; Dionisi-Vici
et al 2006; Hörster et al 2007).
With early diagnosis through newborn screening and im-
proved pediatric care, women with inborn errors of metabo-
lism are achieving reproductive age more frequently and are
well enough to contemplate pregnancy (Langendonk et al
2011; Jacquemyn et al 2014). Patients with MMA who are
pregnant or interested in becoming pregnant, as well as their
health care providers, need information surrounding the risks
to maternal and fetal health that may be associated with the
disease state during pregnancy and monitoring guidelines to
ensure optimal outcomes.
Because some inborn errors have known deleterious ma-
ternal or fetal effects in pregnancy (Koch et al 1993), gesta-
tion, parturition, and lactation can be challenging for the fetus,
mother, and themedical teams. In urea cycle disorders, there is
an increased risk of metabolic decompensation for the mother,
especially in the peripartum period (Walter 2000). Maternal
phenylketonuria has well-described teratogenic effects on the
fetus, including intellectual disability, microcephaly, congen-
ital heart disease, and intrauterine growth retardation, mandat-
ing tighter dietary management for women even prior to
conception (Walter 2000). In addition to the inherent expo-
sures from the maternal condition on the fetus, many condi-
tions are treated with medical foods and supraphysiological
levels of cofactors, vitamins, even though teratogenicity of
these agents have not been studied.
Amongst women with MMA and related disorders, there
are nine published cases of pregnancy affected by maternal
isolatedmethylmalonic acidemia (Wasserstein et al 1999; Diss
et al 1995; Deodato et al 2002; Boneh et al 2002; Adeyemi
et al 2004; Brunel-Guitton et al 2010; Langendonk et al 2011;
Lubrano et al 2013; Jacquemyn et al 2014). The paucity of
information regarding management and outcomes of pregnan-
cies affected by maternal MMAmotivated a critical reapprais-
al of this topic when we participated in the care of several
MMA patients evaluated as part of a natural history study who
had previous pregnancies or became pregnant during the
course of this study.
Patients and methods
A retrospective analysis was performed of patients enrolled
through a natural history study at the National Institutes of
Health, 04-HG-0127 “Clinical and Basic Investigations of
Methylmalonic Acidemia and Related Disorders”
(clinicaltrials.gov identifier: NCT00078078) and conducted
in compliance with the Helsinki Declaration. Prenatal and
delivery records were obtained for review and used to supple-
ment patient assessments. The subtypes of MMA were
determined by cellular biochemistry and/or genetic testing
for all participants (Baumgartner et al 2014).
Two women enrolled in the natural history study were
found to have three unpublished pregnancies. Additionally,
another woman enrolled in the natural history study became
pregnant and was followed prospectively. Two first trimester
miscarriages were also identified; including one in a patient
with another completed pregnancy.
To supplement the experience of our participants, a com-
prehensive literature review of reports indexed in PubMed
describing pregnancies affected by maternal MMA was per-
formed using the terms methylmalonic acidemia, pregnancy,
and inborn errors of metabolism. The searches yielded 28
reports; upon further evaluation, three were relevant to our
study for further review. Additional case reports were also
identified after examining the citations within relevant papers.
Only cases of isolated MMA were considered in subsequent
analyses. The same literature search was repeated in October
2014 prior to final submission. The results of the published
cases and the NIH patients were combined with the previously
published reports to generate the case series presented here.
Results
Nine pregnancies affected by isolated MMAwere previously
published (Adeyemi et al 2004; Boneh et al 2002; Deodato
et al 2002; Diss et al 1995; Jacquemyn et al 2014;
Langendonk et al 2011; Lubrano et al 2013; Wasserstein
et al 1999). In the review of patients enrolled in our clinical
research protocol, four pregnancies in three women with
forms of isolated MMA were identified, as well as two first
trimester miscarriages. These latter pregnancies have not pre-
viously been reported. The results from the literature review
and the retrospective chart review were combined for a total
case series of 13 completed pregnancies (Tables 1 and 2);
three first trimester miscarriages and one first trimester termi-
nation of pregnancy were also documented (Table 3).
Of the 12 women with MMA, several subtypes of MMA
are represented. Five of the patients were unclassified. Four
patients had mut− and three patients had cblA deficiency, one
of whom had two completed pregnancies. The women man-
ifested a range of MMA-related complications including optic
atrophy, chronic pancreatitis, strokes, seizure disorders, histo-
ry of coma, intellectual disability, and cardiomyopathy
(Table 1).
Renal dysfunction is a commonmanifestation ofMMA (de
Baulny et al 2005; Hörster et al 2007) and patients in this
cohort displayed a range of kidney disease from normal func-
tion to renal insufficiency and even renal transplantation (Ta-
ble 1). As previously noted, but worth being emphasized, the
woman reported by Wasserstein et al experienced a decrease
in renal function during pregnancy from 51 ml/min in the first
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Table 1 Published and unpublished pregnancies complicated by maternal isolated methylmalonic acidemia (MMA)
Patient Year of
publication
or delivery
Age Enzymology/
complementation
group
Molecular genetics B12
responsive
Protein intake
(trimester)
Treatments Methylmalonic acid
serum μM (trimester)
Methylmalonic
acid urine
mmol/mol Cr
Renal function
Serum Cr μmol/L
(trimester)
Complications of
MMA
1 (Diss 1995) 1995 23 NR NR No 3.6 g/kg/day (1) NR 16.4 (1) 2.59 mmol/day
(1)
NR Convulsions
4.1 g/kg/day (2) 7.5 (3) 1.02 mmol/day
(3)
1.6 g/kg/day (3)
2a (this report) 1997 18 mut− MUT c.2150G>T
p.G717V; 2nd
mutation
unknown
No 64 g/day Carnitine 172 (postpartum) NR Serum creatinine
70.72
(postpartum)
Strokes, seizure
3a (this report) 1997 24 cblA MMAA c.450dupG
p.P151AfsX19
homozygous
Yes up to 45 g/day N/A 52 (postpartum) NR NR None
3b (this report) 2008 35 cblA MMAA c.450dupG
p.P151AfsX19
homozygous
Yes 45 g/day (1–2) Carnitine,
hydroxocobalamin IM
5 mg QOD, protonix,
albuterol inhaler
214 (preconception) N/A Serum creatinine
120.22 (1)
None
80 g/day (3) 39 (1) 97.24 (3)
45 (2) eGFR:56 mL/min/
A (3)
15 (3) Proteinuria:
280 mg/24 h (3)
4 (Wasserstein) 1999 20 mut− NR No 40–55 g/day Oral amoxicillin in first
trimester then
metronidazole;
cornstarch in overnight
formula; oral
bicarbonate
1900 (1) NR eGFR:51 ml/min/
1.73 m2 (1);
36 ml/min/
1.73 m2 (2)
Optic atrophy,
chronic
pancreatitis,
anemia
484 (2) Proteinuria: 0.7 g in
24 h (2)
1059-1192(3)
5 (Deodato) 2002 24 mut− NR Yes NR Carnitine, vitamin B12 IM
5 mg per week
280 (D) 17,049 (1) Creatinine
clearance:
67.5 ml/min/
1.73 m2
4177 (2)
3236 (3)
1148 (D)
6 (Boneh) 2002 16 cblA NR Yes NR Vitamin B12 IM 1 mg
every 4 weeks increased
to 1 mg every 2 weeks
3.7–9.7 (D) 210–600 (3) NR None
277–1308 (D)
7 (Adeyemi) 2004 23 NR NR Yes Low Protein Oral cyanocobalamin 500
umg BID
NR NR NR Epilepsy
8a (Langendonk) 2011 24 decreased propionate
incorporation
NR unknown 45 g/day (1–2) Carnitine, oral vitamin B12
1 mg daily, folic acid,
iron, calcium,
potassium, vitamin D
758 (Pre) Serum creatinine 50 None
60 g/day (3) 1700–3886 (?)
9 (Langendonk) 2011 19 decreased propionate
incorporation and
methylmalonyl CoA
mutase activity;
reduced adenosyl-
cobalamin synthesis
NR No 35 g/day Carnitine, multivitamin,
vitamin B12 IM 1 mg
every 4–6 weeks
120 (1) 2240 (1) Serum creatinine 66 Intellectual disability
(IQ 55)37 (3) eGFR >90 mL/min/
1.73 m2
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trimester to 36 ml/min in the second trimester. Serum creati-
nine values ranged from 0.63 mg/dL to 1.36 mg/dL (Table 1).
Renal indices are summarized in Table 1 and were not uni-
formly reported (n=9).
MMA patients were largely unaffected by metabolic
disturbances during the pregnancies. One report mentioned
two episodes of mild hyperammonemia (up to 49 μmol/L)
during pregnancy (Langendonk et al 2011). Patient 2 had
two metabolic crises in pregnancy around 24 weeks gesta-
tion, which manifested with nausea, vomiting, and lethargy
and resulted in the need for hospitalizations and IV hydra-
tion. Fortunately, she was without metabolic crises in the
postpartum period.
Protein restriction continued to represent the mainstay of
treatment for patients with MMA during pregnancy. Depend-
ing on the severity of the underlying enzyme deficiency, a
variety of protein restriction methods were employed starting
as low as 40 g of natural protein per day up to 80 g. Patient 2a
was maintained pre-pregnancy on protein restriction at 64 g
per day, which was maintained during pregnancy This patient
is mut− and clinically vitamin B12 unresponsive. Her meta-
bolic course was significant for repeat hospitalizations from
age 6 months to 7 years for metabolic crises but was unre-
markable after that. Pregnancy 3a and 3b, who are the same
patient, had protein intake during pregnancy of 76–80 g per
day.
Patient 3b preconceptionally was prescribed 40 g of protein
per day, which as pregnancy progressed was gradually in-
creased to 80 g per day although actual intake based upon
her recall was about 70 g per day. Her plasma amino acids
were evaluated each trimester and the diet was adjusted based
upon those data. Serum methymalonic acid concentrations
ranged from 66.23 μmol/L in the serum in the first trimester
to 210 μmol/L in the third trimester.
In addition to protein restriction, the use of supple-
ments such as vitamin B12 and carnitine were continued
throughout pregnancy. Patients who have been previously
successfully managed with supraphysiological doses of
vitamin B12 have been maintained on their dosage
throughout pregnancy. Patient 3b was maintained on
hydroxycobalamin 5 mg intramuscular every other day
throughout pregnancy and during labor and delivery
(Table 1).
Specific to the experience with patient 3b in labor and
delivery during an episode of acute stress due to possible
placental abruption and preeclampsia, recommendations
were to administer L-carnitine at 50 mg per kg per dose
intravenously every 6 for 24 h and then decrease the
dosage to 25 mg per kg per dose every 6 h intravenously
until stabilized. Throughout pregnancy, the patient was
maintained on a dose of L-carnitine 1500 mg twice per
day by mouth. Seven of the 13 pregnancies were supple-
mented with carnitine.T
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Table 2 Published and unpublished pregnancies with maternal methylmalonic acidemia, pregnancy outcomes
Patient Enzymology/
complementation group
Metabolic imbalance
in pregnancy
Gestational age
at delivery
Obstetrical
complications
Method
of delivery
Indication for
delivery method
Birth weight (%) Outcome of child
1 (Diss 1995) NR None Term Hyperemesis in first
trimester
Vaginal N/A 3500 g (25 %) At age 3 years, normal
development
2a (This report) mut− Hospitalization and
IV fluids twice at
24 weeeks
38 weeks Postpartum infection Cesarean Fetal distress 3288 g (50 %) At age 10 years, normal
development
3a (This report) cblA None 42 weeks Preeclampsia Cesarean Fetal distress 3714 g (50 %) At age 14 years, normal
development
3b (This report) cblA None 32 weeks Preeclampsia, PPROM,
gestational diabetes,
placental abruption,
uterine scar
Cesarean Fetal distress,
repeat cesarean
delivery
1459 g (10 %) At age 3 years, normal
development
4 (Wasser-stein
1999)
cblA None 36 weeks 4 days PPROM, preeclampsia Vaginal N/A 3220 g (75 %) At age 1 year, normal
development
5 (Deodato 2002) NR None 38 weeks None Cesarean Scheduled, elective 2940 g (25 %) At age 2 years, normal
development
6 (Boneh 2002) decreased propionate
incorporation
None 36 weeks None Cesarean Fetal distress Not reported Not reported
7 (Adeyemi
2004)
decreased propionate
incorporation
and methylmalonyl
CoA mutase
activity; reduced
adenosyl-cobalamin
synthesis
None 34 weeks PPROM, chlamydia Cesarean Failure to progress 1900 g (10 %) At age 5 months, normal
development
8a (Langendonk
2011)
NR 2 episodes of
hyperammonemia
(49μmol/L)
38 weeks None Vagnial N/A 2850 g (10–25 %) At age 5 years, normal
growth and
development
9 (Langendonk
2011)
mut
− None 35 weeks Intrauterine growth
restriction (IUGR)
Cesarean IUGR 1530 g (<3 %) At age 1 year, normal
growth and
development
10 (This report) mut− None 39 weeks None Vaginal N/A 3095 g (25 %) At age 3 months,
normal appearance
11 (Lubrano
2013)
cblA None 37 weeks None Vaginal N/A 2480 g (10 %) At age 30 months,
normal
development
12 (Jacquemyn
2014)
cblA None 40 weeks None Vaginal N/A 3300 g (50 %) Follow up reported
as normal
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Gestational diabetes complicated one pregnancy in our
cohort. She was managed less vigorously than gestational
diabetic patients without MMA would be to avoid hypogly-
cemia and catabolism. The goals set for the patient were to
maintain blood glucose levels at 120 mg/dl to prevent catab-
olism. Despite the laxity in glucoregulation, the birth weight at
delivery was 10th centile.
The literature review revealed four of the nine (44.4 %)
pregnancies resulted in a cesarean delivery as well as four of
the nine (44.4 %) resulted in preterm deliveries. One case
report noted the development of preeclampsia in a patient
who was reported to have renal insufficiency (Wasserstein
et al 1999). Additional cases from the National Institutes of
Health demonstrated three of the four pregnancies resulted in
cesarean deliveries all with emergent indications of fetal dis-
tress. Two of the four pregnancies were complicated by
preeclampsia.
Combining our case series with that of the literature review,
38.5 % of the completed pregnancies resulted in preterm
deliveries. A cesarean delivery rate of 53.8% (7/13) was noted
among the cohort, which is higher than the United States
national average of 32.8 % (CDC 2014). Fetal distress or
nonreassuring fetal status was the indication for more than
half (4/7) of the cesarean deliveries, and another report docu-
mented persistently nonreactive fetal heart tracings with
reassuring biophysical profiles (Wasserstein 1999). An addi-
tional indication for cesarean delivery in the setting of mater-
nal MMA was intrauterine growth restriction (Langendonk
et al 2011).
The postpartum courses for the patients were unremark-
able. Patients were hospitalized for 2–10 days postpartum. All
were maintained with dextrose containing intravenous fluids.
Patients 2a, 3a, 3b, 10 were slowly introduced to protein
postpartum as tolerated. To our knowledge, there have been
no published reports of metabolic decompensation postpartum
in a mother with MMA.
Fetal growth and development appear to be unaffected by
maternal elevations of MMA (Wasserstein et al 1999). In-
creased MMA levels in amniotic fluid have been reported in
patients undergoing invasive prenatal testing. Malformations
or adverse outcomes in the babies were not reported although
persistence of high concentrations of maternal metabolites
was documented in one case report (Wasserstein et al 1999;
Deodato et al 2002).
Discussion
Asmore patients with inborn errors of metabolism not only reach
child bearing age but feel well enough to pursue pregnancy, the
clinical challenges of counseling and management will continue
to become more common. In MMA, the information used to
manage patients during pregnancy has been derived from case
reports and assumptions made from the experiences of other
inborn errors of metabolism. Although in some inborn errors of
metabolism, such as phenylketonuria, elevated levels of bio-
chemical precursors are clearly teratogenic, the same information
has not yet been established for MMA. It should be noted that
one infant born to a mother with MMA had IUGR (Langendonk
et al 2011) and that protein limitation during pregnancy might be
associatedwith serious iatrogenic complications, given that a low
protein intake is associated with poor fetal growth in mothers
who havemalnutrition (Godfrey et al 1995). In addition to risk to
the developing fetus, proper counseling needs to include any
potential complications impacting maternal health, such as preg-
nancy related complications including preeclampsia and gesta-
tional diabetes mellitus (GDM).
A variety of subtypes of MMA were identified including
three cases with cblA (four pregnancies), four cases of mut-
(one cobalamin responsive, three non-responsive), two histor-
ical cases confirmed with only enzymology, and three cases
with an unknown type of MMA (two B12 responsive and one
unresponsive). The cases span several decades and therefore
include varying methods of management of MMA as well as
changing methods of pregnancy management. Although lim-
ited in its numbers, this case series presents published experi-
ences along with a number of new cases to create the most
comprehensive description of MMA in pregnancy to date and
helps to provide the foundation for improved understanding,
management, and counseling of MMA patients desiring
pregnancy.
When reviewing all the cases together, we observed some
possible trends. Pregnancy complications such as late preterm
birth, preterm premature rupture of membranes, cesarean de-
livery, nonreassuring fetal status, and preeclampsia all have
been documented in this small cohort, while birth weight and
development despite exposure to methylmalonic acid in utero
appears to be tolerated without incidence in the offspring. In
support of this concept, there have been no reports of birth
defects or intellectual disability related to exposure to elevated
Table 3 Pregnancy loss in first
trimester patients with MMA Patient Enzymology Timing of pregnancy loss
2b Mut – B12 unresponsive First trimester spontaneous miscarriage
8b (Langendonk) Not performed Miscarriage at 5 weeks gestational age
8c (Langendonk) Not performed Termination of pregnancy at 10 weeks gestational age
13 Mut –B12 unresponsive First trimester spontaneous miscarriage
844 J Inherit Metab Dis (2015) 38:839–846
levels of methylmalonic acid in utero; in fact, 11 of the 13
children, ranging in age between 3 months to 14 years, born to
mothers with MMA have reported normal developmental
outcomes.
In the postpartum period, no episodes of decompensation
have been reported, although in theory this period may present
the window of highest risk for metabolic decompensation
based upon experiences with urea cycle disorders (Walter
2000; Langendonk et al 2011). The postpartum period is a
time of catabolism with the involution of the uterus and the
breakdown of protein. In theory, the excess amino acids
generated during this time can increase BCAA oxidative flux
and increase nitrogen load, and could contribute to the pre-
cipitation of a metabolic crisis.
Pregnancy is an anabolic state, which for some patients
with inborn errors of metabolism might make control of their
disease slightly easier. Dietary needs of protein increase nat-
urally as the pregnancy progresses and increased dietary in-
take of protein would need to be maintained postpartum if the
patient were to breastfeed. Although all cases but one thus far
have reported normal fetal growth despite protein restriction,
the risk of protein malnutrition for the mother and the fetus
necessitates careful metabolic management. It has been our
recommendation to serially follow fetal growth with ultra-
sounds throughout the pregnancy, and to adjust maternal and
fetal protein needs using maternal biochemical parameters.
Vitamin B12 responsive patients are treated with
supraphysiological doses of cobalamin. Although vitamin
B12 deficiency can be adequately treated in pregnancy with-
out adverse consequences related to treatment, it is not known
where the upper limit of vitamin B12 treatment in pregnancy
lies, if such a ceiling exists, and whether cofactors in high
doses could contribute to an adverse pregnancy outcome. Of
the pregnancies, 7/13 were supplemented with carnitine. Pa-
tients ingested high doses of carnitine with the same caveats
that very little is known about carnitine supplementation in
pregnancy (Winter et al 1995). The effect of carnitine supple-
mentation on birth parameters needs to be studied further.
Optimization of the maternal condition prior to pregnancy
and close dietary management combined with regular surveil-
lance of maternal serum amino acids is important to ensure
maternal nutrition and minimize dietary risk of catabolism.
Delivery plans should be discussed with the patient especially
in light of the increased rate of late preterm birth and cesarean
deliveries. In the intrapartum period, avoidance of catabolism
with intravenous dextrose should be maintained in labor and
delivery. The most prudent approach to a pregnancy compli-
cated by a maternal inborn error of metabolism is via a multi-
disciplinary team that includes a biochemically trained genet-
icist, metabolic dietitian, and maternal-fetal medicine special-
ist working together with an obstetrician.
In the case of maternal phenylketonuria, a pregnancy reg-
istry has proven invaluable to collect patient experiences and
use the aggregate data to adjust practice patterns (Vockley et al
2014; Koch et al 1993). The information presented here
should be useful in the continued surveillance and counseling
of future patients, and will help stimulate the formation of a
dedicated registry to define the natural history of pregnancy in
MMA and related disorders.
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